Precision Genomic Testing Market Report 2025

The precision genomic testing market size has grown rapidly in recent years. It will grow from $13.44 billion in 2024 to $15.0 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. Growth in the historic period can be attributed to the increasing availability of direct-to-consumer genetic testing, rising collaborations between pharmaceutical and diagnostic companies, a heightened focus on preventive healthcare, greater adoption of companion diagnostics, and growing awareness of the importance of early disease detection.

The precision genomic testing market size is expected to see rapid growth in the next few years. It will grow to $23.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. Growth in the forecast period can be attributed to the rising demand for precision oncology solutions, increased focus on rare disease diagnostics, growing investment in population genomics initiatives, expanded use of multi-omics approaches, and the rising demand for non-invasive prenatal testing. Key trends expected during this period include advancements in next-generation sequencing technologies, innovations in liquid biopsy techniques, integration of artificial intelligence in genomic analysis, improvements in multi-omics data interpretation, and the evolution of direct-to-consumer genetic testing models.

The increasing prevalence of genetic disorders is anticipated to drive the growth of the precision genomic testing market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual’s DNA, which may involve mutations in a single gene, multiple genes, or structural or numerical changes in chromosomes. This rise in genetic disorders is largely attributed to the increasing maternal age, as older mothers face a higher risk of having children with chromosomal abnormalities, such as Down syndrome. Precision genomic testing allows for early detection and accurate diagnosis of genetic disorders by identifying specific genetic mutations, which supports targeted interventions and personalized treatment plans. For example, in May 2025, Gene People, a UK-based registered charity, reported that genetic conditions affect approximately 1 in 25 children, impacting over 2.4 million individuals in the UK. Additionally, around 30,000 newborns and children are diagnosed with a genetic condition each year in the UK. As a result, the rising incidence of genetic disorders is fueling the growth of the precision genomic testing market.

Companies in the precision genomic testing market are focusing on the development of advanced technologies, such as ultra-sensitive circulating tumor DNA assays, to improve early cancer detection and diagnostic accuracy. These assays are capable of identifying minute fragments of tumor-derived DNA present in the bloodstream, which enables earlier and more precise detection of genetic mutations associated with cancer. For instance, in April 2025, Natera Inc., a US-based clinical genetic testing company, launched the ultra-sensitive Signatera genome molecular residual disease test. This test applies whole genome sequencing of both the patient's tumor and matched normal DNA to create a personalized assay, enabling detection of circulating tumor DNA at extremely low concentrations - down to 1 part per million. Such high sensitivity allows for earlier detection of cancer recurrence, improving treatment planning and patient care across multiple cancer types.

In November 2022, Myriad Genetics Inc., a US-based healthcare company, acquired Gateway Genomics LLC for $67.5 million. This acquisition was aimed at strengthening Myriad Genetics’ women’s health portfolio by expanding into the early prenatal testing segment. The addition of Gateway Genomics’ SneakPeek early gender DNA test broadens Myriad’s offerings in the consumer genetic testing space. Gateway Genomics LLC, based in the US, specializes in the development of genetic-based tests for consumers, particularly focused on early prenatal applications.

Major players in the precision genomic testing market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Ambry Genetics Corporation, Color Health Inc., Pacific Biosciences, Eurofins Genomics LLC, and Precision Genetics.

North America was the largest region in the precision genomic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in precision genomic testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the precision genomic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precision genomic testing market consists of revenues earned by entities by providing services such as gene panel testing, whole genome and exome analysis, pharmacogenomics testing, cancer genomics profiling, hereditary disease screening, and bioinformatics-driven interpretation of genetic data. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision genomic testing market also includes sales of hybridization buffers and enzymes, targeted gene panels, library preparation kits, genomic data compression tools, and rare mutation detection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The precision genomic testing market research report is one of a series of new reports that provides precision genomic testing market statistics, including precision genomic testing global market size, regional shares, competitors with precision genomic testing market share, detailed precision genomic testing market segments, market trends and opportunities, and any further data you may need to thrive in the precision genomic testing industry. The precision genomic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision genomic testing involves the use of advanced genetic analysis to detect specific DNA variations or mutations that impact an individual’s risk of disease, diagnosis, prognosis, or treatment response. This approach supports personalized healthcare by enabling tailored prevention strategies, therapeutic interventions, and drug selection based on a person’s unique genetic profile.

The key products and services in precision genomic testing include consumables, equipment, and services. Consumables are items intended for single or repeated use and are depleted through routine procedures, examples include laboratory reagents and medical supplies. The testing employs a variety of advanced technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray technology, Sanger sequencing, and CRISPR-associated systems. It is applied across multiple areas, including oncology, cardiovascular diseases, neurological disorders, reproductive health, rare diseases, and more. End users include hospitals and clinics, diagnostic laboratories, research and academic institutions, among others.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.